With all the mergers, acquisitions and new companies popping up in the pharmaceutical and biotechnology contract research industry, it is hard to know who you can trust with your drug development program. Often times clients are wary of being the first to place a full IND program with a new company. The perceived risk is often high and there are many unknowns. New companies might not have experienced staff or established procedures or don’t know all the proper guidelines to follow.
Although Attentive is a new boutique company name, we are not new to the CRO industry. For example, every one of our study directors has a minimum of 12 years’ experience within the industry. We have an established process that encompasses all aspects of the non-clinical in-vivo development environment. Furthermore, we know all the GLP required SOPs that detail the need for clear delineation of responsibility and accountability and protocols within the study. Our proactive regulatory compliance was built into our strategy for you prior to becoming Attentive.
We pride ourselves on being Attentive in all aspects of our business. All of our practices support the claim we make in our name – we are Attentive to every regulatory guideline, documented detail, and every protocol. We are veterans within the industry and working with us takes the fear out of working with a new company. Our established team and processes have helped get drugs and products successfully to market. Our team is not new – they have become more Attentive.
Let us show you the Attentive way, schedule an executive briefing and/or a virtual lab tour with us today.